Widmark A, et al. - Via the Scandinavian HYPO-RT-PC phase 3 trial, an open-label, randomized, non-inferiority trial done conducted in 12 centers in Sweden and Denmark on 1,200 men up to 75 years of age with intermediate-to-high-risk prostate cancer, researchers intended to show the non-inferiority of ultra-hypofractionation to conventional fractionation. Significantly greater levels of acute urinary and bowel symptoms were seen in the ultra-hypofractionation group vs the conventional fractionation group. No significant increases in late symptoms were seen, other than increased urinary symptoms at 1-year follow-up, which was consistent with the physician-evaluated toxicity. With regard to failure-free survival, ultra-hypofractionated radiotherapy was observed as non-inferior to conventionally fractionated radiotherapy for intermediate-to-high risk prostate cancer. Although late toxicity was comparable in both treatment groups, early side-effects were more apparent with ultra-hypofractionation. Therefore, the utility of ultra-hypofractionation for radiotherapy of prostate cancer was suggested.